Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Latest Chinese Regulations for Imported Drug Registration
2.
Pharmaceutical Distribution in Europe The Emergence of Direct-to-Pharmacy Supply
3.
eHealthInsight Series Reaching Doctors and Patients Through New Digital Media
4.
Emerging markets series Benchmarking key countries Brazil, Russia, India, China and Turkey
5.
Commercial Insight Infectious Diseases Overview
6.
Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture?
7.
Stakeholder Insight Diabetes
8.
Urinary Incontinence Lifecycle management strategies retain midterm market growth
9.
Commercial Insight Autoimmune Overview Market continues to prosper
10.
Generics Series Key trends and events in the 7 major markets
Best Sellers:
1.
The Global Non-Opioid Market in Pain Management 2007-2022
2.
Antibiotics and Drug Resistance 2007
3.
Generics Series Key trends and events in the 7 major markets
4.
Global Ophthalmic Market Analysis and Forecasts to 2012
5.
Handbook of Pharmaceutical Additives
6.
BioNewsCast Press Release Distribution Service
7.
Cancer Diagnostic Testing World Markets
8.
The World Allergy Market 2006-2011 - The Rx-OTC Rush
Clinical Diagnostics in China: Market Sector Analyses and Participant Directory
There has not been a year in the last decade in which the IVD market in China has failed to grow. With a gross domestic product of over $1.4 trillion, China surpassed Italy last year to become the worlds sixth largest economy, according to the International Monetary Fund. This country of 1.3 billion people is now Americas sixth largest export market, and Chinas economy, which has been growing at an average rate of 8% over the last 20 years, grew over 9% last year.
Combined with this impressive overall growth, a number of recent events and trends in the Chinese healthcare environment are making China an increasingly attractive market opportunity for in vitro diagnostics companies. Chinas accession to the World Trade Organization (WTO) has made doing business in China much easier for diagnostic companies by reducing tariffs and opening the door for foreign firms to control their own distribution. The increasing numbers of private laboratories and expanded reference laboratories are expanding the market for tests of all kinds.
Although there are a number of challenges for diagnostic manufacturers to understand and overcome, the market for clinical diagnostics in China (both reagents and instruments) remains one of the most promising emerging markets in the world.
The report covers seven market segments:
Coagulation
Critical Care Chemistry
Hematology
Immunochemistry
Molecular Testing
Routine Chemistry
Urine Chemistry
For each segment, the report provides key market data such as market size, number of labs and their workload, level of automation, and market share for both instrument and reagent competitors, foreign and domestic.
Perhaps the most valuable part of the report, however, is the extensive listing of market participants. The report profiles:
24 international manufacturers active in China, their local contacts and distributors, and discussing their position in the Chinese IVD market
88 domestic manufacturers, their contact information, specialties, and products
57 local distributors, their contact information and companies represented (and a distributors cross-reference allows the reader to easily look up who is distributing for whom)
This report, produced jointly with the firm McEvoy & Farmer, is the product of years of on-the-ground research in China. Although the focus is on what is happening now, the report provides historical background from McEvoy & Farmers 10+ years of studying IVD markets in Asia and particularly China.
November 1, 2005
PDF
254 Pages
Table of Contents
Price: $4,995.00 / GBP2,497.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.